Erasca Inc

NASDAQ:ERAS   10:50:48 AM EDT
11.32
+0.28 (+2.54%)
Products, Strategic Combinations

Erasca Announces FDA Clearance Of IND Application For Eras-801 In Glioblastoma Multiforme And Collaboration With GCAR For Potential Inclusion In Gbm Agile Clinical Trial

Published: 12/17/2021 13:06 GMT
Erasca Inc (ERAS) - Erasca Announces FDA Clearance of Ind Application for Eras-801 in Glioblastoma Multiforme and Collaboration With Gcar for Potential Inclusion in Gbm Agile Clinical Trial.
Erasca Announces FDA Clearance of Ind Application for Eras-801 in Glioblastoma Multiforme and Collaboration With Gcar for Potential Inclusion in Gbm Agile Clinical Trial.
Erasca Inc- Ind Filing Achieved Ahead of Schedule; Sees Dosing of First Patient in Thunderbbolt-1 Phase 1 Clinical Trial in Recurrent Gbm in Q1 2022.
Erasca Inc - Early Collaboration With Gcar Could Support Potential Registrational Path in Gbm.